Search

Your search keyword '"FINASTERIDE"' showing total 323 results

Search Constraints

Start Over You searched for: Descriptor "FINASTERIDE" Remove constraint Descriptor: "FINASTERIDE" Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
323 results on '"FINASTERIDE"'

Search Results

1. Patient‐reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data.

2. Therapeutic maintenance effect of finasteride 1 mg every other month regimen in androgenetic alopecia and study on the difference in response to finasteride treatment: A prospective cohort study.

3. Post‐finasteride syndrome: real or myth?

4. Clinical effectiveness of finasteride versus hydroxychloroquine in the treatment of frontal fibrosing alopecia: A randomized controlled trial.

5. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: A blinded randomized clinical trial

6. Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor blinded, 3‐arm, pilot trial.

7. The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study.

8. Clinical study on the efficacy and tolerability of a topical regenerative treatment in patients with telogen effluvium and mild androgenetic alopecia.

9. Selenium in combination with a tomato lipid extract as a therapy for benign prostatic hyperplasia and its alterations in rats with induced BPH.

10. Re: The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA): A population‐based case–control study.

11. Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia—A randomized controlled trial.

12. Topical finasteride for male and female pattern hair loss: Is it a safe and effective alternative?

13. 5‐Alpha reductase inhibitor related litigation: A legal database review.

14. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.

15. Electronic Circular Dichroism Imaging (ECDi) Casts a New Light on the Origin of Solid‐State Chiroptical Properties.

16. The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia and androgenetic alopecia: A population-based case-control study.

17. Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single‐blinded, active‐controlled trial.

18. Platelet‐rich plasma with low dose oral minoxidil (1.25mg versus 2.5mg) along with trichoscopic pre‐ and post‐treatment evaluation.

19. A prospective clinical and transcriptomic feasibility study of oral‐only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity.

20. Origanum vulgare L. leaves extract alleviates testis and sperm damages induced by finasteride: Biochemical, Immunohistological and apoptosis genes based evidences.

21. Protocatechuic acid ameliorates testosterone‐induced benign prostatic hyperplasia through the regulation of inflammation and oxidative stress in castrated rats.

22. Placebo‐controlled dose‐effect studies with topical minoxidil 2% or 5% in male‐patterned hair loss treated with oral finasteride employing an analytical and exhaustive study protocol.

23. Postnatal exposure to finasteride causes different effects on the prostate of male and female gerbils.

24. Nucleus‐specific modulation of phasic and tonic inhibition by endogenous neurosteroidogenesis in the murine thalamus.

25. Inflammatory pathway employed by Red Maca to treat induced benign prostatic hyperplasia in rats.

26. Characteristics of finasteride users in comparison with nonusers: A Nordic nationwide study based on individual‐level data from Denmark, Finland, and Sweden.

27. Low‐dose in utero exposure to finasteride promotes developmental changes in both male and female gerbil prostates.

28. Is there a role for 5α‐reductase inhibitors in transgender individuals?

29. "Comparison of QR 678® & QR678® Neo as monotherapy and as combination therapy with 5% Minoxidil solution and oral Finasteride in the treatment of male androgenetic alopecia—Which is better?".

30. Viable terminal scalp hair follicles constitute a necessary and sufficient biological end‐organ that conditions clinical efficacy of finasteride in males with male pattern hair loss without implying reversal of miniaturized follicles.

31. Sex hormones modulate pathogenic processes in experimental traumatic brain injury.

32. Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a survey‐based, single‐centre, controlled study.

33. The efficacy and use of finasteride in women: a systematic review.

34. Impact of 5α‐reductase inhibitor and α‐blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.

35. Evaluation of long‐term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system.

36. A randomized, double‐blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.

37. Efficacy of non‐surgical treatments for androgenetic alopecia: a systematic review and network meta‐analysis.

38. Excellent response to mesotherapy as adjunctive treatment in male androgenetic alopecia.

39. Statin medications and the risk of gynecomastia.

40. Imaging prostate cancer (PCa) with [99mTc(CO)3]finasteride dithiocarbamate.

41. Finasteride accelerates prostate wound healing after thulium laser resection through DHT and AR signalling.

42. Risk of rhabdomyolysis from 5‐α reductase inhibitors.

43. Finasteride inhibited brain dopaminergic system and open‐field behaviors in adolescent male rats.

44. Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries.

45. Fibrillar collagen genes are not coordinately upregulated with TGF β1 expression in finasteride-treated prostate.

46. Hidradenitis Suppurativa in Children Treated with Finasteride-A Case Series.

47. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.

48. Assessing finasteride-associated sexual dysfunction using the FAERS database.

49. Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5α-reductase inhibitor treated individuals as compared with an untreated cohort.

50. 5α-Dihydrotestosterone negatively regulates cell proliferation of the periurethral ventral mesenchyme during urethral tube formation in the murine male genital tubercle.

Catalog

Books, media, physical & digital resources